Pascal Soriot, AstraZeneca CEO (via Getty images)
October 20, 2021 10:24 AM EDTUpdated 02:12 PM
R&D
FDA+

FDA slaps As­traZeneca's MCL-1 can­cer drug with a hold af­ter safe­ty is­sue — 2 years af­ter Am­gen axed a trou­bled ri­val

John Carroll

Editor & Founder

There are new ques­tions be­ing posed about a class of can­cer drugs in the wake of the sec­ond FDA-en­forced clin­i­cal hold in the field. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times